Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Designation

Radiation Oncologist

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Carlo Ruperto Aguilar is a board-certified Radiation Oncologist with over 23 years of clinical experience, having obtained his medical license in March 2000. He has been actively serving in various oncology centers where he provides expertise in cancer care and tomotherapy.

A graduate of the University of Santo Tomas, Dr. Aguilar completed both his Doctor of Medicine and Bachelor’s degree in Medical Technology at UST. He pursued further training in radiation oncology at Jose P. Reyes Memorial Medical Center.

With multiple affiliations across key cancer centers in Luzon and continued participation in both local and international oncology forums, Dr. Aguilar remains deeply engaged in advancing cancer treatment through evidence-based radiation therapy.

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Brachytherapy
Intraoperative Radiotherapy (IORT)

General Oncology with Special Interest

Schedule

Day	9:00 am – 12:00 pm	2:00 pm – 5:00 pm
Monday	-	-
Tuesday	-	-
Wednesday	-	-
Thursday	by appointment	by appointment
Friday	-	-

To schedule an appointment, please call or text 0956 172 8218

Media coverage

Teresita Mandal: Story of Hope and Trust in the Lord

Excellence in Cancer Care in the midst of Pandemic

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

IOC Cares

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Radiation Oncologist

Dr. Gonzalo C. Banuelos, Jr.

Radiation Oncologist

Dr. Jerickson Abbie S. Flores

Radiation Oncologist

Dr. Karl Jeremy B. Lo

Radiation Oncologist

Dr. Misael C. Cruz

Radiation Oncologist

Dra. Cynthia Tan-Pusag

Radiation Oncologist

Dra. Fritzie C. Villegas

Radiation Oncologist

Dra. Marigie C. Olvina

Radiation Oncologist

Dra. Thelma S. Sarmiento

Radiation Oncologist

Radiation Oncologists

Dr. Gonzalo C. Banuelos, Jr.
MD, FPCR, FPROS, FPSO

Designation

Consultant Clinical Oncologist

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Gonzalo Banuelos Jr. is a board-certified Radiation Oncologist with advanced international training and multi-institutional affiliations. He completed his Doctor of Medicine at the University of the East Ramon Magsaysay Memorial Medical Center and underwent residency training in Radiation Oncology at Jose R. Reyes Memorial Medical Center. His post-graduate internship was at East Avenue Medical Center.

With additional in-service and technical training in Japan, the Netherlands, and Germany, Dr. Banuelos brings a globally informed approach to cancer treatment, especially in Image-Guided Radiation Therapy (IGRT) and Tomotherapy.

Dr. Banuelos is a Fellow of the Philippine Radiation Oncology Society, the Philippine College of Radiology, and the Philippine Society of Oncologists, and has held leadership roles including Executive Council Member and Secretary of the Philippine Society of Oncologists.

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Brachytherapy
Intraoperative Radiotherapy (IORT)
Gamma-knife
Radioactive Iodine (RAI) Therapy

General Oncology with Special Interest

Schedule

Day	9:00 am – 1:00 pm	2:00 pm – 5:00 pm
Monday	-	-
Tuesday	by appointment	by appointment
Wednesday	-	-
Thursday	-	-
Friday	-	-

To schedule an appointment, please call or text 0956 172 8218

Singapore Medical Council (SMC) – full registration (1997 – present)
Malaysia Medical Council (MMC) – full registration (2005 – present)
Singapore Society of Oncology
South-East Asian Radiation Oncology Group (SEAROG)
American Society of Clinical Oncology (ASCO)
American Society for Radiation Oncology (ASTRO)
Malaysian Oncological Society (Life member)

Nasopharyngeal Cancer

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein Barr Virus-Specific Autologous T Lymphocytes versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients. (Tessa Therapeutic Sponsored International Multicentre Trial)
Role: Principal Investigator
Development of A Gamma-delta T Cells Therapeutic Regimen for Human Nasopharyngeal Carcinoma. (BMRC grant - Investigator Initiated Trial)
Role: Principal Investigator
Presentation: Singapore General Hospital Scientist Award 25 April 2008
Publication: Cancer Immunology, Immunotherapy 2009; 58:1095-1107
A Randomized Phase II Study to Investigate the Effects of Recombinant Intestinal Trefoil Factor (ITF) on Oral Mucositis in Patients Receiving Radiation Therapy for Nasopharyngeal Cancer. (GI Company Sponsored Trial)
Role: Co-Investigator
CT-PET vs Conventional Staging in Nasopharyngeal Carcinoma. (SingHealth Research Grant)
Role: Principal Investigator
Presentation: ASTRO Annual Meeting 2007
Publication: Head Neck 2009; 31:346-54
Randomized Phase II Triplet Chemotherapy Regime (Gemcitabine/ Cisplatin/ Paclitaxel) followed Concurrent Cisplatin-RT in Nasopharyngeal Carcinoma. (BMRC Research Grant)
Role: Co-Investigator
Modified Suppressive Subtractive Hybridization (MSSH) & Real-time PCR Analysis of sera in Nasopharyngeal cancer patients pre-post radical radiotherapy (Molecular Research Unit, NCC Singapore)
Role: Principal Investigator

Breast Cancer

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC). (MSD Sponsored International Multicentre Trial)
Role: Co-Investigator
An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribocliclib (LEE11) in Combination with Letrozole for the Treatment of Men and Postmenopausal Women with Hormone Receptor-Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (ABC) with No Prior Hormonal Therapy for Advanced Disease. (Novartis Sponsored International Multicentre Trial)
Role: Co-Investigator
A Randomized, 3 Arm, Multicentre, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined with Pertuzumab or T-DM1 Combined with Pertuzumab-Placebo (Blinded for Pertuzumab), versus the Combination of Trastuzumab plus Taxane, as First Line Treatment in HER2- Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer (MBC). (Roche Sponsored International Multicentre Trial)
Role: Principal Investigator
Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Brest Cancer in Asia (Pfizer Sponsored International Multicentre Trial)
Role: Co-Investigator
An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribocliclib (LEE11) in Combination with Letrozole for the Treatment of Men and Postmenopausal Women with Hormone Receptor-Positive (HR+), HER2-negative (HER2-) Advanced Breast Cancer (ABC) with No Prior Hormonal Therapy for Advanced Disease (Novartis Sponsored International Multicentre Trial)
Role: Co-Investigator
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355) (MSD Sponsored International Multicentre Trial)
Role: Co-Investigator
A Phase III Double-Blind Randomisation Study Accessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-Line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (CAPitello-290) (AstraZeneca Sponsored International Multicentre Trial)
Role: Co-Investigator
A Two-part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2-Positive Advanced Breast Cancer with a PIK3CA Mutation (EPIK-B2) (Novartis Sponsored International Multicentre Trial)
Role: Co-Investigator
A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss without PIK3CA Mutation (EPIK-B3) (Novartis Sponsored International Multicentre Trial)
Role: Co-Investigator
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) (AstraZeneca Sponsored International Multicentre Trial)
Role: Principal Investigator
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy- Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer (MI3475-B49) (MSD Sponsored International Multicentre Trial)
Role: Co-Investigator

Lung Cancer

A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Celltrion Sponsored International Multicentre Trial)
Role: Co-Investigator
A Multiple Center, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) versus Gemcitabine/ Cisplatin as the First-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Patients with Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors. (Roche Sponsored International Multicentre Trial)
Role: Principal Investigator
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1. (MSD Sponsored International Multicentre Trial)
Role: Co-Investigator
A Multi-Country, Multi-Centre, Observational, Retrospective Study to Reveal the Patient Characteristics, Disease Burden, Treatment Patterns and Patient Journey of Stage III Non-Small-Cell Lung Cancer Patients. (AstraZeneca Sponsored International Multicentre Trial)
Role: Co-Investigator
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. (Regeneron Sponsored International Multicentre Trial)
Role: Co-Investigator
A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Celltrion Sponsored International Multicentre Trial)
Role: Co-Investigator
A Phase II Single-Arm Study to Investigate Tepotinib Combined with Osimertinib in MET Amplified, Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior 1st to 3rd Generation EGFR-Tyrosine Kinase Inhibitor Therapy (INSIGHT-2) (Merck KGaA Sponsored International Multicentre Trial)
Role: Co-Investigator
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ARC-10) (Arcus Bioscience Sponsored International Multicentre Trial)
Role: Principal Investigator
Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review
Role: Principal Investigator
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8) (AstraZeneca Sponsored International Multicentre Trial)
Role: Principal Investigator
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy (PALOMA-3) (Janssen Sponsored International Multicentre Trial)
Role: Principal Investigator
A Phase III, Double blind, Randomised, Placebo Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2 IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA-2) (AstraZeneca Sponsored International Multicentre Trial)
Role: Co-Investigator

Cervical Cancer

Head and Neck Cancer

Phase III Randomised Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer. (Sanofi-Aventis Sponsored Trial)
Role: Co-Investigator
Publication: J Clin Oncol 2008; 28: 2989 - 2995
Phase III, Double-Blinded, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy with or without Nimotuzumab for Stage III/ IV Head and Neck Squamous Cell Cancer. (Innogene Sponsored International Trial)
Role: Principal Investigator

Liver Cancer

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) versus Placebo and BSC as Second-Line Treatment in Patients with Hepatocellular Carcinoma following First-Line Therapy with Sorafenib. (ImClone/ Eli Lilly Sponsored International Multicentre Trial)
Role: Principal Investigator
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) (AstraZeneca Sponsored International Multicentre Trial)
Role: Principal Investigator

Colorectal Cancer

Aspirin for Dukes C and High-Risk Dukes B Colorectal Cancers – An International, Multi-Centre, Double-Blind Randomised Placebo-Controlled Phase III Trial. (Singapore Clinical Research Institute Sponsored trial)
Role: Principal Investigator
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007) (MSD Sponsored International Multicentre Trial)
Role: Co-Investigator

Stomach Cancer

Ovarian Cancer

Biliary Tract Cancer

Thyroid Cancer

SL Morris, SH Low, RP A’ Hern, TG Eisen, ME Gore, CM Nutting, KJ Harrington. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. British Journal of Cancer 2004; 91:829-833.
J.S.H. Low, D.M.K.Heng, J.T.S. Wee. The Question of T2a and N3a in the UICC/AJCC (1997) staging system for nasopharyngeal carcinoma. Clinical Oncology (R Coll Radiol) 2004; 16(8): 581- 583.
John SH Low, Eu-Tiong Chua, Joseph..TS Wee. Stereotactic Radiosurgery (SRS) plus Intracavitary Irradiation (ICI) in the salvage of rT1 and rT2 persistent and recurrent Nasopharyngeal Carcinoma (NPC), Lung Cancer 2004, 46(S1): S50.
J SH Low, EH Wong, HS KhooTan, SP Yap, VJ Sethi, EJ Chua, J Low, EH Tay, LT Soh. Adjuvant Sequential Chemotherapy and Radiotherapy in Uterine Papillary Serous Carcinoma. Gynecologic Oncology 2005; 97(1): 171-177.
John S.H Low, Fei Gao, Ta Wen Yu, Jeffrey Tuan, Ivan Tham, Hoon Seng Khoo Tan, Tong Hong Khor. Curative Radiotherapy in Elderly patients with cervix cancer – do they fare worse compared to their younger counterparts? Int J Rad Oncol Bio Phys 2005, 63(2S1): S347.
John SH Low, Eu Tiong Chua, Fei Gao, Joseph TS Wee. Stereotactic Radiosurgery plus Intracavitary Irradiation in the salvage of Nasopharyngeal Carcinoma (NPC). Head Neck 2006; 28(4): 321-329.
J SH Low, KB Ng. Modified Fletcher's 3 Channel Brachytherapy System with Vaginal Line Source Loading versus Uterine Tandem & Vaginal Cylinder System in Stage IIIA Cervical Cancer. Biomed Imaging and Interv J 2006; 2(1): e15.
L Wong, HT See, HS KhooTan, JS Low, WT Ng, JJ Low. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer 2006; 16(3): 1364-9.
J SH Low, WY Koh, SP Yap, KW Fong. Radical Radiotherapy in stage I Non-Small Cell Lung Cancer (NSCLC) – Singapore National Cancer Centre Experience. Ann Acad Med Singapore 2007; 36(9):778-83.
Chua ML, Ong SC, Wee JT, Ng DC, Gao F, Tan TW, Fong KW, Chua ET, Khoo JB, Low JS. Comparison of 4 modalities in distant metastatic staging in endemic nasopharyngeal carcinoma. Head Neck.2009; 31(3):346-54.
Puan KJ, Low JS, Tan TW, Wee JT, Tan EH, Fong KW, Chua ET, Jin C, Giner JL, Morita CT, Goh CH, Hui KM. Phenotypic and functional alterations of carcinoma. Cancer Immunology, Immunotherapy 2009; 58(7):1095-1107.
SP Heng, S Kandaiya, John low Seng Hooi. The influence of the bowel and bladder preparation protocol for radiotherapy of prostate cancer using kilo-voltage cone beam CT. Indian Journal of Cancer 2013.
SP Heng, SH Low, S Kandaiya. Increased in dose to organ at risks did not correlate with the weight loss but did correlate with the lateral neck dimension reduction and volume changes for head and neck patients treated with intensity-modulated radiotherapy. Head Neck Oncol 2014 May 03;6(1):9.
L.I. Tan, S.H. Low, N. Mat-Nor, S.P. Heng. Quality of Life in Nasopharyngeal Cancer (NPC) Patients: Study of Salivary Flow Recovery Pattern on Xerostomia Improvement for Intensity Modulated Radiation Therapy (IMRT) Versus Volumetric Modulated Arc Therapy (VMAT). Int J Rad Oncol Bio Phys 2014, 90(1S): S525:2795.
Norfadilah Mat Nor, R. Ahmad, Heng Siew Peng, L.S.H. John et al. Immobilisation precision in VMAT for oral cancer patients. Journal of Physics Conference Series May 2017; 851(1): 012025.
Ho GF, Chai CS, Alip A, Wahid MI, Abdullah MM, Foo YC, How SH, Zaatar A, Lam KS, Leong KW, Low JS. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC cancer. 2019 Dec;19(1):1-1.
Md Yusof M, Abdullah MM, Yap BK, Ng SC, Low JS, Lam KS, Ahmad Badruddin RB, Lai CN, Lau KL, Chong KJ, Nonis JG. Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Asia‐Pacific Journal of Clinical Oncology. 2021 Nov 23.
Gao QL, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Low J. L-MOCA: An open-label study of olaparib maintenance monotherapy in platinumsensitive relapsed ovarian cancer. Journal of Clinical Oncology 2021; 39, no. 15_suppl.
Gao, Q., Zhu, J., Zhao, W., Huang, Y., An, R., Zheng, H., Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Low J. & Ma, D. Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer: Phase III trial (L-MOCA). Clinical Cancer Research 2022, 28(11), 2278-2285.
Wu L, Li J, Xu C, Biswas B, Tang K, Wang H, Liu Z, Batra U, Ho GF, Low SH, Lu Y. 1337P Real-world utilization and outcomes of dacomitinib as first-line positive NSCLC: An interim analysis of the ARIA study. Annals of Oncology. 2023 Oct 1;34:S771.

Media Coverage

Media Coverage

27 February 2026

Teresita Mandal: Story of Hope and Trust in the Lord

Media Coverage

27 February 2026

Excellence in Cancer Care in the midst of Pandemic

Media Coverage

27 February 2026

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

Media Coverage

27 February 2026

IOC Cares

Media Coverage

27 February 2026

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Media Coverage

27 February 2026

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Radiation Oncologist

Dr. Gonzalo C. Banuelos, Jr.

Radiation Oncologist

Dr. Jerickson Abbie S. Flores

Radiation Oncologist

Dr. Karl Jeremy B. Lo

Radiation Oncologist

Dr. Misael C. Cruz

Radiation Oncologist

Dra. Cynthia Tan-Pusag

Radiation Oncologist

Dra. Fritzie C. Villegas

Radiation Oncologist

Dra. Marigie C. Olvina

Radiation Oncologist

Dra. Thelma S. Sarmiento

Radiation Oncologist

Radiation Oncologists

Dr. Jerickson Abbie S. Flores
MD, FPSO, FPCR, DPBR-RO

Designation

Radiation Oncologist

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr.Jerickson Abbie S. Flores, MD, FPCR, DPBR-RO graduated with honors (magna cum laude) both in his undergraduate degree in Medical Technology and Doctorate degree in Medicine at University of Santo Tomas. He obtained his residency training in Radiation Oncology at the Department of Radiotherapy – Jose R. Reyes Memorial Medical Center, Manila, Philippines and is a fellow of the Philippine College of Radiology and Philippine Society of Oncologists, Inc.

Dr. Flores had his Fellowship training in Advanced Radiation Oncology at Seoul National University Hospital, South Korea. He had his observership training for Image Guided Brachytherapy at the Gunma University – Graduate School of Medicine, Japan.

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Intraoperative Radiotherapy (IORT)

General Oncology with Special Interest

Day	8:00 am – 12:00 pm	1:00 pm – 5:00 pm
Monday	-	-
Tuesday	-	by appointment
Wednesday	-	-
Thursday	by appointment	-
Friday	-	-

To schedule an appointment, please call or text 0917-899-6626

Fellow of the Royal College of Physician, London, England
Fellow of the Royal College of Radiologists, London, England
Fellowship in Radiation Oncology, University of Toronto, Canada
Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers

Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)

Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Radiation Oncologists

Dr. Karl Jeremy B. Lo
MD, MBA, RN, DPBR

Designation

Radiation Oncologist

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Karl Jeremy B. Lo is a board-certified Radiation Oncologist and healthcare leader. With a strong foundation in both medicine and nursing, Dr. Lo holds a Doctor of Medicine and a Master in Business Administration from the Ateneo School of Medicine and Public Health. He is also a registered nurse and obtained his BS in Nursing from the University of the Philippines – Manila.

He has been actively practicing in the field of radiation oncology since completing residency in 2019. His areas of clinical interest include modern radiotherapy techniques and multidisciplinary cancer care.

Dr. Lo has participated in national research forums and received recognitions for his academic presentations. He is actively involved in professional societies and has delivered lectures and attended specialized training in both clinical oncology and healthcare management.

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Intraoperative Radiotherapy (IORT)

General Oncology with Special Interest

Day	8:00 am – 12:00 pm	1:00 pm – 5:00 pm
Monday	-	-
Tuesday	-	by appointment
Wednesday	-	-
Thursday	by appointment	-
Friday	-	-

To schedule an appointment, please call or text 0917-899-6626

Fellow of the Royal College of Physician, London, England
Fellow of the Royal College of Radiologists, London, England
Fellowship in Radiation Oncology, University of Toronto, Canada
Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers

Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)

Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Radiation Oncologists

Dr. Misael C. Cruz

Designation

Medical Director

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Misael Cabigting Cruz is a seasoned Radiation Oncologist with over two decades of clinical experience. He completed his Doctor of Medicine degree at Angeles University Foundation and pursued a Radiation Oncology Fellowship at St. Luke’s Medical Center from 1999 to 2002, where he also served as Chief Fellow.

He holds multiple advanced degrees, including Master of Science in Clinical Epidemiology from the University of the Philippines Manila, Master of Science in Clinical Nutrition from PWU–St. Luke’s Medical Center, and a fellowship with the Philippine College of Hospital Administrators. He is board-certified by the Philippine Board of Radiation Oncology and is a Fellow of the Philippine Radiation Oncology Society, the Philippine Society of Oncology, and other local and international medical organizations.

Dr. Cruz has trained extensively both locally and internationally, completing advanced programs in intraoperative radiotherapy, tomotherapy, brachytherapy, image-guided radiation, and intensity-modulated radiation therapy at institutions in Germany, Singapore, Belgium, and the Netherlands.

He is also the Medical Director of the OncoCare Philippines and has held academic and leadership roles in both hospital and academic settings. His research and publications have contributed to advancements in prostate, lung, and head and neck cancer treatment, particularly in the field of brachytherapy and chemoradiation.

Procedure focus

General Oncology with Special Interest

Schedule

Day	9:00 am – 1:00 pm	2:00 pm – 5:00 pm
Monday	by appointment	by appointment
Tuesday	by appointment	by appointment
Wednesday	by appointment	by appointment
Thursday	by appointment	by appointment
Friday	by appointment	by appointment

To schedule an appointment, please call or text 0956 172 8218

Head and Neck Cancer Clinical Trials

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally advanced stage IV locally recurrent/metastatic Nasopharyngeal Carcinoma
Role: Co-Investigator
Place: National Cancer Institute Singapore
Phase 1b/11 open label study evaluating the combination of bevacizumab priming with pembrolizumab in EBER-ISH positive Nasopharyngeal carcinoma
Role: Co-Investigator
Place: National Cancer Institute Singapore
Nivolumab in combination with chemoradiation for patients with stage II-IVb Nasopharyngeal carcinoma, A phase II study
Role: Co-Investigator
Place:National Cancer Institute Singapore
A phase 2 study of ALX148 in combination with Pembrolizumab in Patients with Advanced Head and NECK Squamous Cell Carcinoma (ASPEN03)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase II randomized trial of induction cisplatin and gemcitabine and vs Cisplatin, Gemcitabine, Bevacizumab and Pembrolizumab in Nasopharyngeal Cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore

Breast Cancer Clinical Trials

Phase II ASLAN001 combined with weekly paclitaxel and Herceptin in HER2 positive stage 1-3 breast cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
Phase II, Single Arm, Open Label, Simon Two-Stage Study of pembrolizumab in metastatic HER 2 negative breast cancer patients:evaluation of impact of germline variants in APOBEC3B (AUROR)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase 3, Randomized, Multi-Center, Open-Label Study of Trastuzumab Deruxtecan vs Investigators Choice of Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose disease has progressed on Endocrine Therapy in the Metastatic Setting (DestinyBreast06)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive HER2 negative breast cancer, who have progressed on CDK 4.6 inhibitors (ELEVATE)
Role: Co-Investigator
Place: National Cancer Institute Singapore
EPIK-B4: A Phase II, multicenter, randomized open label, active-controlled study to assess the safety and efficacy of dapagliflozin +metformin XR versus metformin during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER 2-, advanced breast cancer with PIK#CA mutation following progression on/after endocrine-based therapy
Role: Co-Investigator
Place: National Cancer Institute Singapore
A randomized, multicenter, Double Blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant chemotherapy and Adjuvant Endocrine Therapy in Patients with High risk, Estrogen Receptor-Positive(ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER 2 -) Primary Breast Cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase II, randomized, open label, multicenter study evaluating the efficacy and safety of GDC- 9545 compared with Physician’s Choice of Endocrine Monotherapy in Patients with Previously treated with Estrogen Receptor-Positive, HER 2 negative Locally advanced or metastatic breast cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine(T-DM1) for subjects with unresectable locally -advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)
Role: Co-Investigator
Place: National Cancer Institute Singapore

Lung Cancer Clinical Trials

Improvement in the value of orally administered cancer drugs: Osimertinib for advanced EGFRpositive NSCLCL patients-a phase II study
Role: Co-Investigator
Place: National Cancer Institute Singapore
HERTHENA-Lung01, a Phase II Trial of PAtritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Caner after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Role: Co-Investigator
Place: National Cancer Institute Singapore
A phase Ib Multicenter, Open-Label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecanand Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-Line treatment of patients with advanced or metastatic non squamous Non Small Cell Lung Caner and HER2 Over expression ( Destiny-Lung 03)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A phase1b/2 study to evaluate the combination of nivolumab (anti PD1 monoclonal Ab) with ADG106 (4-1 BB agonist monoclonal Ab) in metastatic NSCLC after progression with anti PD1 therapy and platinum-based chemotherapy ( ADIVO Lung Study )
Role: Co-Investigator
Place: National Cancer Institute Singapore
A phase 1/2a Study of BMS-986207 Monoclonal Antibody-alone and in Combination with Nivolumab and Ipilimumab in Advanced Solid Tumors
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase III Randomized, Multicenter, Double-Blind, Placebo-controlled Study of Durvalumab for the treatmentof Stage II-III NSCLC patients with Minimal Residual Disease Following Surgery and Curative Intent therapy ( MERMAID-2)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase 1b, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase I/II, Randomized, Double-Blind, Placebo-Controlled study of Carboplatin Plus Etoposide Plus Atezolizumab With or Without Tiragolumab (anti-TIGIT antibody) in patients with untreated Extensive-Stage Small Cell Lung Cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase III, randomized , Double-Blind Study to Assess the Efficacy and safety of Lazertinib versus Gefitinib as First Line Treatment in Patients with Epidermal Growth Factoir Receptor Sensitizing Mutation positive, Locally advanced or metastatic non-small cell lung cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
A phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-tumor activity of TPX-0005 in patients with Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT )
Role: Co-Investigator
Place: National Cancer Institute Singapore

Gastrointestinal and Hepatobiliary cancer Clinical Trials

A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in subjects with HER2-positive Metastatic and/or Unresectable Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma Subjects who have progressed on or after a Trastuzumab - Containing Regimen (DESTINY-Gastric04)
Role: Co-Investigator
Place: National Cancer Institute Singapore
An Open Label Phase 2 study to evaluate the Safety and Efficacy of MTL-CEPBA Administered with Sorafenib in Participants with Hepatocellular Carcinoma(HCC) and Hepatitis B or Hepatitis C virus
Role: Co-Investigator
Place: National Cancer Institute Singapore
A real world study on Lenvatinib in HCC patients in an Academic Cancer Centre
Role: Primary Investigator
Place: National Cancer Institute Singapore

GU cancers Clinical Trials

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects with Metastatic Castrate Resistant Prostate Cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
Randomized, Open-Label, Phase 3 study of Acapatamab vs standard of Care in Metastatic Castrate-Resistant Prostate Cancer(CAPTIVATE)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Randomized Open-Label Phase III study of Sacituzumab Govitecan versus Treatment of Physician’s Choice in Subjects with metastatic Locally Advanced Unresectable Urothelial Cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Randomized Phase 3 study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy alone in Cisplatin-Ineligible Participants with Muscle Invasive Bladder Cancer (Keynote 905/EV 303)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A randomized, Double-Blind, Controlled Phase 3 study of Cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated advanced or metastatic Renal Cell Carcinoma of Intermediate or poor risk
Role: Co-Investigator
Place: National Cancer Institute Singapore
A randomized, open label, multicenter seamless Phase 2/3 study to evaluate the efficacy and safety of rogaritinib ( BAY 1163877) compared with chemotherapy in patients with FGFRpositive locally advanced metastatic urothelial carcinoma who have received prior platinum containing chemotherapy
Role: Co-Investigator
Place: National Cancer Institute Singapore

Gynaecological Cancers Clinical trials

A randomized, Open-Label, Phase 3 trial of Tisotumab Vedotin vs investigator’s choice of chemotherapy in second or third line recurrent or metastatic Cervical Cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore
A Phase III, Multi-center, randomized (1:1), open label, active controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agents cytotoxic chemotherapy in participants with no germline BRCA mutation detected , platinum-resistant or referactory, high-grade serous ovarian cancer (EPIK-O)
Role: Co-Investigator
Place: National Cancer Institute Singapore
A single-arm phase II trial to evaluate the safety and efficacy of the antibody-drug conjugate SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma who previously progressed on or after first line platinum-based chemotherapy
Role: Co-Investigator
Place: National Cancer Institute Singapore
A randomized, multicentre, Double-blind, Placebo-controlled, Phase II Study of First-Line Carboplatin and Paclitaxel in Combination with Druvalumab, followed by maintenance Durvalumab with or without Olaparib in patients with newly diagnosed advanced or Recurrent Endometrial Cancer ( DUO-E)
Role: Co-Investigator
Place: National Cancer Institute Singapore

1. Pericardial effusion in pregnancy; two case reports and a discussion. Asokumaran et al 2015 presented at 9th Asia Pacific Cardiology Update
2. Multiple Intracranial Tuberculoma; a case report and discussion. Asokumaran et al presented at Selangor Research Day 2015
3. Early experience of Immune checkpoint inhibitors in renal cell carcinoma NUH. 5th NCIS Annual Research Meeting 2018. Matilda Lee , Yugarajah Asokumaran , Gloria Chan , Natalie Ngoi , Joan Choo , Vaishnavi Muthu , Huang YQ , Barr Kumarakulasinghe Nesaretnam , Goh Boon Cher , Yong Wei Ping , Balamurugan A , Leong Cheng Nang , Thian Yee Liang , Alvin SC Wong , presented at 5th NCIS Annual Research Meeting 2018
4. A Single Centre Experience Of Genetic Testing In Ovarian Cancer; Utilisation and therapeutic implication . NCAM Annual research meeting 2019Yugarajah A , Pei Yi Ong, Jeffrey JH Low, Joseph SY Ng, Samuel Guan Wei Ow , David SP Tan , Yi Wan Lim , Lim Siew Eng , Soo Chin Lee
5. The role of targeted therapy in treatment of advanced hepatocellular carcinoma in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Rachel Su Jen Wong, Jiaxuan Wu, Alisha Joan Leen, Glenn Jin Chong Tey, Yugarajah Asokumaran, Gloria Chan, Chidambaram Siddappan, Anand Devaprasath Jeyasekharan, Cheng Ean Chee, Wei-Peng Yong, Kee Yuan Ngiam, and Raghav Sundar Journal of Clinical Oncology 2020 38:15_suppl, e16623-e16623
6. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma. ASCO 2021 JCO 38 2020 . Robert John Walsh, Emily Pauline Nickles, Yating Li, Bhushan Dharmadhikari, Mickey Koh, Liam Pock Ho, Marieta Chan, Liang Piu Koh, Michelle Li Mei Poon, Lip Kun Tan, Yiqing Huang, Yvonne Li'en Ang, Wan Qin Chong, Yugarajah Asokumaran, Kwok Seng Loh, Ross A. Soo, Chwee Ming Lim, Herbert Schwarz, Boon Cher Goh
7. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsNavigating the Radiologic Potpourri. 2021 Apr 2;13(7):1689. doi: 10.3390/cancers13071689. PMID: 33918397; PMCID: PMC8038243. Wong A, Vellayappan B, Cheng L, Zhao JJ, Muthu V, Asokumaran Yugarajah , Low JL, Lee M, Huang YQ, Kumarakulasinghe NB, Ngoi N, Leong CN, Chua W, Thian YL
8. Real-work Experience of consolidation durvalumab after concurrent radiotherapy in stage III non-small cell lung cancer 2022 Jun Thoracic Cancer. 13. 10.1111/1759-7714.14667. Huang Yiqing , Zhao Joseph, Soon Yu Yang, Wong, Alvin Wong, Aminkeng Folefac ,Yvonne Ang, Asokumaran Yugarajah, Low Jia Li, Lee Matilda, Joan Choo, Gloria Chan, Adrian Kee, Tay Sen, Goh Boon Cher & Ross Soo
9. Nickles, E., Dharmadhikari, B., Yating, L. Yugarajah Asokumaran et al. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. Cancer Immunol Immunother 71, 1531–1543 (2022)
10. Choon Seong Ang, …Yugarajah Asokumaran et al Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.. JCO 40, 3584 3584(2022). DOI:10.1200/JCO.2022.40.16_suppl.3584
11. Qin Jian Low, Joseph J.Zhao, Racehl Su Jen Wong, Yugarajah Asokumaran et al MO34-4 Advanced Hepatocellular carcinoma viral status and immunotherapy efficacy: A propensityscore matched analysis Annals of Oncology 2023, https://doi.org/10.1016/j.annonc2023.09.240
12. Jia Li Low, Yugarajah Asokumaran et alCost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lun g cancer patients in Asia. JCO 38, e19385-e19385(202) DOI:10.1200/JCO.2020.38.15 suppl.e19385

Media Coverage

Teresita Mandal: Story of Hope and Trust in the Lord

Excellence in Cancer Care in the midst of Pandemic

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

IOC Cares

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Radiation Oncologist

Dr. Gonzalo C. Banuelos, Jr.

Radiation Oncologist

Dr. Jerickson Abbie S. Flores

Radiation Oncologist

Dr. Karl Jeremy B. Lo

Radiation Oncologist

Dr. Misael C. Cruz

Radiation Oncologist

Dra. Cynthia Tan-Pusag

Radiation Oncologist

Dra. Fritzie C. Villegas

Radiation Oncologist

Dra. Marigie C. Olvina

Radiation Oncologist

Dra. Thelma S. Sarmiento

Radiation Oncologist

Radiation Oncologists

Dra. Cynthia Tan-Pusag
MD, FPROS

Designation

Radiation Oncologist

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Cynthia Tan-Pusag is a Radiation Oncologist with over 14 years of clinical experience, having completed her Radiation Oncology residency training at Cardinal Santos Medical Center. She earned her Doctor of Medicine degree from the University of Santo Tomas Faculty of Medicine and Surgery and previously completed her Bachelor of Science in Biology at the University of Santo Tomas.

Dr. Tan-Pusag is currently affiliated with several major medical institutions. Her clinical practice focuses on radiation therapy for cancer management and multidisciplinary oncologic care.

She is an active member of several professional organizations, including the Philippine Radiation Oncology Society, American Society for Radiation Oncology (ASTRO), and the International Society of Intraoperative Radiation Therapy (ISIORT). She has also contributed to oncology research, including studies on radiation therapy–related dermatitis in breast cancer patients and rare lymphoma cases presented at international conferences.

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Intraoperative Radiotherapy (IORT)

General Oncology with Special Interest

Schedule

Day	8:00 am – 12:00 pm	1:00 pm – 5:00 pm
Monday	-	-
Tuesday	-	-
Wednesday	by appointment	by appointment
Thursday	-	-
Friday	-	-

To schedule an appointment, please call or text 0956 172 8218

Fellow of the Royal College of Physician, London, England
Fellow of the Royal College of Radiologists, London, England
Fellowship in Radiation Oncology, University of Toronto, Canada
Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers

Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)

Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Media Coverage

Media Coverage

27 February 2026

Teresita Mandal: Story of Hope and Trust in the Lord

Media Coverage

27 February 2026

Excellence in Cancer Care in the midst of Pandemic

Media Coverage

27 February 2026

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

Media Coverage

27 February 2026

IOC Cares

Media Coverage

27 February 2026

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Media Coverage

27 February 2026

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Radiation Oncologist

Dr. Gonzalo C. Banuelos, Jr.

Radiation Oncologist

Dr. Jerickson Abbie S. Flores

Radiation Oncologist

Dr. Karl Jeremy B. Lo

Radiation Oncologist

Dr. Misael C. Cruz

Radiation Oncologist

Dra. Cynthia Tan-Pusag

Radiation Oncologist

Dra. Fritzie C. Villegas

Radiation Oncologist

Dra. Marigie C. Olvina

Radiation Oncologist

Dra. Thelma S. Sarmiento

Radiation Oncologist

Radiation Oncologists

Dra. Fritzie C. Villegas
M.D., DPCR, FPROS

Designation

Radiation Oncologist

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Fritzie Cabusao-Villegas is a board-certified and Fellow of Philippine College of Radiology in radiation oncology with over two decades of medical experience, including more than a decade of specialized practice in radiation oncology. She earned her medical degree from Angeles University Foundation, graduating as a Class Salutatorian in 1999, and holds a bachelor’s degree in Medical Technology from the same institution. She completed her residency training in Radiation Oncology at Jose R. Reyes Memorial Medical Center from 2009 to 2013 and successfully passed the Diplomate Board Examination in Radiation Oncology in January 2014. She also passed the Philippine Physician Licensure Exam in 2000.

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Intraoperative Radiotherapy (IORT)

General Oncology with Special Interest

Schedule

Day	8:00 am – 12:00 pm	1:00 pm – 5:00 pm
Monday	-	-
Tuesday	by appointment	by appointment
Wednesday	-	-
Thursday	by appointment	by appointment
Friday	-	-

To schedule an appointment, please call or text 0956 172 8218

Fellow of the Royal College of Physician, London, England
Fellow of the Royal College of Radiologists, London, England
Fellowship in Radiation Oncology, University of Toronto, Canada
Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers

Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)

Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.

Fellow of the Royal College of Physician, London, England
Fellow of the Royal College of Radiologists, London, England
Fellowship in Radiation Oncology, University of Toronto, Canada
Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers

Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)

Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Media Coverage

Media Coverage

27 February 2026

Teresita Mandal: Story of Hope and Trust in the Lord

Media Coverage

27 February 2026

Excellence in Cancer Care in the midst of Pandemic

Media Coverage

27 February 2026

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

Media Coverage

27 February 2026

IOC Cares

Media Coverage

27 February 2026

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Media Coverage

27 February 2026

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Radiation Oncologist

Dr. Gonzalo C. Banuelos, Jr.

Radiation Oncologist

Dr. Jerickson Abbie S. Flores

Radiation Oncologist

Dr. Karl Jeremy B. Lo

Radiation Oncologist

Dr. Misael C. Cruz

Radiation Oncologist

Dra. Cynthia Tan-Pusag

Radiation Oncologist

Dra. Fritzie C. Villegas

Radiation Oncologist

Dra. Marigie C. Olvina

Radiation Oncologist

Dra. Thelma S. Sarmiento

Radiation Oncologist

Radiation Oncologists

Dra. Marigie C. Olvina, MD

Designation

Section Head, Tomotherapy

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Marigie Olvina is a board-certified Radiation Oncologist with over 23 years of experience in the field of radiation therapy. She obtained her Doctor of Medicine degree from the University of Santo Tomas (1997) and completed her internship at Veterans Memorial Medical Center. She then underwent specialized residency training in Radiotherapy at the Jose R. Reyes Memorial Medical Center from 1999 to 2002.

Certified by the Philippine Radiation Oncology Society in 2003, Dr. Olvina has since built an extensive career providing expert radiation oncology services in both public and private institutions across the Philippines.

Her professional affiliations include the European Society of Therapeutic and Radiation Oncology, Philippine Radiation Oncology Society (former board member), and the Philippine Society of Oncologists, where she is a Fellow.

Dr. Olvina’s commitment to excellence in cancer care is further reflected in her active participation in international conferences, numerous guest lectures, and research contributions, particularly in advanced treatment planning and IMRT (Intensity-Modulated Radiation Therapy).

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Brachytherapy
Intraoperative Radiotherapy (IORT)
Gamma-knife

General Oncology with Special Interest

Schedule

Day	9:00 am – 1:00 pm	2:00 pm – 6:00 pm
Monday	-	-
Tuesday	-	-
Wednesday	by appointment	by appointment
Thursday	-	-
Friday	-	-

To schedule an appointment, please call or text 0956 172 8218

Principal investigator for OP-1250-301/OPERA -01. A phase 3 Randomised , open-label study of OP-1250 Monotherapy VS standard of care for the treatment of ER+ve, HER2-ve Advanced or metastatic breast cancer following endocrine and CDK4/6 inhibitor therapy.
Sub-principal investigator for ARCHERY clinical trial. Artificial Intelligence based radiotherapy treatment planning for cervical and head and neck cancer.
Sub-principal investigator for Exelixis. A Randomised open-label phase 3 study of XL092+Nivolumab vs sunitinib in subjects with advanced or metastatic non-clear cell renal carcinoma.
Sub-principal investigator for INAVO. A Phase III, Randomized , double blind, placebo-controlled study evaluating the efficacy and safety of inavolisib plus Palbociclib and fulvestrant versus placebo plus pablociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer.
Key team member on the retrospective study comparing postmastectomy breast cancer patients with breast implant who had radiotherapy versus surgery alone between 2014-2020. Involved in developing the standard/ criteria, questionnaires for patients and data collection. The project is still on going and expected to complete in August 2021.
First author in retrospective study on the correlation of distance between a central tumour and central structures and the effect on survival for patients receiving lung SABR (stereotactic ablative radiotherapy.) Responsible in developing the objective, data collection, perform statistical analysis and summarising the report. As a result of this study, it has demonstrated that the central location of the tumour may predict the overall survival in patients receiving stereotactic ablative radiotherapy to the lung. Abstract has been accepted by the World Conference on Lung Cancer 2021 and poster due to be presented orally on the 8th of September 2021.
First author in retrospective study to compare dosimetric difference on treatment volume (PTV cm3) and lung V20 in patients receiving lung stereotactic ablative radiotherapy (SABR) based on use of abdominal compression. Responsible in developing the objective, data collection, perform statistical analysis and summarising the report This study has shown a non-significant trend towards reduced PTV and lung V20 in a cohort of patients whereby virtue of tumour position we would have expected the values to be larger than our comparator group. We conclude this is evidence supporting the use of abdominal compression and suggest this could be extended to other situations where reducing the PTV size may be beneficial eg treatment of more central tumours. Abstract has been accepted by the British Thoracic Oncology Group (BTOG) Conference. Poster was presented on the 23rd of April 2021.
Co-author in auditing the changes in the management of patients having radical radiotherapy for lung cancer in the UK during the COVID-19 pandemic (COVID-RT Lung). This is a multicentre UK audit which involved patients with stage 1-3 lung cancer referred for radical radiotherapy between April and October 2020. Patients with alterations in their management during COVID- 19 pandemic and those who continue with standard management are included in the audit. As a result, the COVID-19 pandemic has resulted in increased use of hypofractionated and ultrahypofractionated radiotherapy schedules. The outcome was presented in the National Cancer Research Institute conference in October 2020. Abstract was submitted to the World Conference on Lung Cancer.
Lead and first author of a retrospective study on the outcome of PARP-Inhibitor as a maintenance therapy in patients with newly diagnosed advanced ovarian cancer and platinum -sensitive recurrent ovarian cancer. An audit to assess real life experience in South Yorkshire between January 2017-December 2019. Involved in developing the criteria, data collections, analysing data and report summary. The results indicate that BRCA mutation patients have better outcome compared to BRCA negative patients. Overall median time between commencement of treatment and disease progression for both BRCA and non-BRCA is 8 months. The study was completed in May 2018 and was presented in the local Postgraduate Medical Education Meeting on the 16th of August 2019. This was also reviewed in the annual appraisal and received excellent feedbacks and further re-auditing will follow.
Co-author of the retrospective study of the outcome and factors predicting survival and completion of Radium 223 in metastatic castrate resistant Prostate Cancer (mCRPC). Involved in developing the criteria, data collections and result discussions. The study has showed that overall median survival of 4.5 months for Ra-223 patients observed inferior to that reported for both the Ra-223 and placebo group (14.3 vs 11.2months) in ALSYMPCA trial. PSA does not reflect response to Ra-223 treatment. Alkaline phosphatase is a marker of bone turnover and has been used as a surrogate marker for disease response. A higher neutrophil-to-lymphocyte ratios is also an independent survival predictor in mCRPC patients receiving Ra-223. This audit was published in the Clinical Oncology Journal Volume 30, Issue 9, September 2018, Pages 548-555 2017.
Lead and involved in audit on monitoring heart failure in GP practice in 2007. Developed the criteria, involved in data collections, summary report and presentation. The outcome of the audit has led to development of a standard Performa as part of the follow up in heart failure patients.
National Audit in Stroke in 2006. Key team member responsible in data collections.
Audit on Managing of Acute Gastroenteritis in children in 2006. Developed the criteria, questionnaires, data collection and analysing data. As a result, this has led to a development of a Performa that has been used in Children’s Outpatient, admission unit and A&E.

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Radiation Oncologist

Dr. Gonzalo C. Banuelos, Jr.

Radiation Oncologist

Dr. Jerickson Abbie S. Flores

Radiation Oncologist

Dr. Karl Jeremy B. Lo

Radiation Oncologist

Dr. Misael C. Cruz

Radiation Oncologist

Dra. Cynthia Tan-Pusag

Radiation Oncologist

Dra. Fritzie C. Villegas

Radiation Oncologist

Dra. Marigie C. Olvina

Radiation Oncologist

Dra. Thelma S. Sarmiento

Radiation Oncologist

Media Coverage

Teresita Mandal: Story of Hope and Trust in the Lord

Excellence in Cancer Care in the midst of Pandemic

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

IOC Cares

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Radiation Oncologists

Dra. Thelma S. Sarmiento, M.D.

Designation

Radiation Oncologist
Board Certified – Philippine Radiation Oncology Society

Speciality

Qualification

License number

Languages

English, Tagalog

Location

About the Doctor

Dr. Thelma Sebastian-Sarmiento is a seasoned and highly respected Radiation Oncologist with decades of clinical experience in cancer care, specializing in radiation therapy. She completed her residency in Radiation Oncology at Jose R. Reyes Memorial Medical Center and obtained her Philippine Board of Radiation Oncology certification following her medical licensure.

Throughout her distinguished career, Dr. Sarmiento has served as a consultant in multiple premier cancer institutions across the Philippines. She has also held key leadership roles, including serving as Treasurer of the Philippine Radiation Oncology Society and as a Board Examiner for the Philippine Board of Radiology in Radiation Oncology.

She has been involved in numerous clinical research projects and international training programs, with a strong presence in seminars and congresses globally. Her research contributions include work on the benefits of spirulina in mitigating radiation side effects, image-guided radiation therapy, and hypofractionated IMRT for prostate cancer.

Procedure focus

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Radiotherapy (SRT)
Stereotactic Radiosurgery (SRS)
Stereotactic Body Radiation Therapy (SBRT)
Intraoperative Radiotherapy (IORT)

General Oncology with Special Interest

Schedule

Day	8:00 am – 12:00 pm	1:00 pm – 5:00 pm
Monday	-	-
Tuesday	by appointment	by appointment
Wednesday	-	-
Thursday	-	-
Friday	-	-

To schedule an appointment, please call or text 0956 172 8218

Fellow of the Royal College of Physician, London, England
Fellow of the Royal College of Radiologists, London, England
Fellowship in Radiation Oncology, University of Toronto, Canada
Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers

Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)

Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.

Fellow of the Royal College of Physician, London, England
Fellow of the Royal College of Radiologists, London, England
Fellowship in Radiation Oncology, University of Toronto, Canada
Previous member of the United Kingdom National Cancer Research Institute in designing and managing national trials head and neck and thyroid cancers

Chief investigator: Phase 3 randomised of XL-184 (Cabozantinib) versus placebo in unresectable, locally advanced or metastatic thyroid medullary carcinoma
Principal investigator: Phase 3 PARSPORT (parotid sparing radiotherapy) in Head and neck cancer.
Principal investigator: Phase 3 HILO trial. High dose versus low dose radioiodine with or without recombinant human thyroid stimulating hormone for remnant ablation following surgery for differentiated thyroid cancer.
Principal investigator: Phase 3 ION trial. Is radioiodine ablation necessary in low risk thyroid cancers. Principal investigator. Phase 3 randomised trial using sorafenib versus placebo in metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Principal investigator: Phase 3 randomized trial Determination of Quality of Life Instrument most preferred by patients with thyroid cancer (DETEQT)
Principal investigator: Phase 3 randomised trial to compare the effects of two doses of vandetanib (150mg Vs 300mg) in patients with advanced medullary thyroid cancer
Co-investigator: Phase 2 EXTREME study (Cetuximab and platinum based chemotherapy in recurrent or metastatic head and neck cancers.
Co-investigator: Phase 2 synchronous Capecitabine and radiotherapy in locally advanced head and neck cancers.
Co-investigator: Phase 3 randomised trial of zalutumumab with best supportive care in patients with non-curable head and neck squamous cell carcinoma who have failed standard platinum based chemotherapy.
Co-investigator. Phase I/II radiotherapy dose escalation and cetuximab study in intermediate stage head and neck cancer. (INTENSE)
Co-investigator. X-ray volumetric imaging of parotid to enable dose monitoring during parotid sparing intensity modulated radiotherapy (X-PERT)
Co-investigator. Study of the impact of co-registering CT and MRI compared with CT alone in the planning of head and neck carcinoma (PRECISE)

Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
The role of neoadjuvant chemotherapy in the surgical management of women with breast cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, Yoke-Ching Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021

Media Coverage

Media Coverage

27 February 2026

Teresita Mandal: Story of Hope and Trust in the Lord

Media Coverage

27 February 2026

Excellence in Cancer Care in the midst of Pandemic

Media Coverage

27 February 2026

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

Media Coverage

27 February 2026

IOC Cares

Media Coverage

27 February 2026

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Media Coverage

27 February 2026

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Radiation Oncologist

Dr. Gonzalo C. Banuelos, Jr.

Radiation Oncologist

Dr. Jerickson Abbie S. Flores

Radiation Oncologist

Dr. Karl Jeremy B. Lo

Radiation Oncologist

Dr. Misael C. Cruz

Radiation Oncologist

Dra. Cynthia Tan-Pusag

Radiation Oncologist

Dra. Fritzie C. Villegas

Radiation Oncologist

Dra. Marigie C. Olvina

Radiation Oncologist

Dra. Thelma S. Sarmiento

Radiation Oncologist

Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Designation

Speciality

Qualification

License number

Languages

Location

About the Doctor

Procedure focus

General Oncology with Special Interest

Schedule

Media coverage

Teresita Mandal: Story of Hope and Trust in the Lord

Excellence in Cancer Care in the midst of Pandemic

Day in the Life of a Radiotherapist: A COVID-19 Frontliner

IOC Cares

Pananampalataya at Lakas ng Loob: Kwento ni Reginald Zerna

Story of Faith, Courage and a Mother’s Love – Jennifer Sunga’s Cancer Journey

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Dr. Gonzalo C. Banuelos, Jr.

Dr. Jerickson Abbie S. Flores

Dr. Karl Jeremy B. Lo

Dr. Misael C. Cruz

Dra. Cynthia Tan-Pusag

Dra. Fritzie C. Villegas

Dra. Marigie C. Olvina

Dra. Thelma S. Sarmiento

Radiation Oncologists

Dr. Gonzalo C. Banuelos, Jr.MD, FPCR, FPROS, FPSO

Designation

Speciality

Qualification

License number

Languages

Location

About the Doctor

Procedure focus

General Oncology with Special Interest

Schedule

Media Coverage

Other Radiation Oncologists

Dr. Carlo Ruperto P. Aguilar

Dr. Gonzalo C. Banuelos, Jr.

Dr. Jerickson Abbie S. Flores

Dr. Karl Jeremy B. Lo

Dr. Misael C. Cruz

Dra. Cynthia Tan-Pusag

Dra. Fritzie C. Villegas

Dra. Marigie C. Olvina

Dra. Thelma S. Sarmiento

Radiation Oncologists

Dr. Jerickson Abbie S. FloresMD, FPSO, FPCR, DPBR-RO

Designation

Speciality

Qualification

License number

Languages

Location

About the Doctor

Procedure focus

General Oncology with Special Interest

Radiation Oncologists

Dr. Karl Jeremy B. LoMD, MBA, RN, DPBR

Designation

Speciality

Qualification

License number

Languages

Location

About the Doctor

Procedure focus

General Oncology with Special Interest

Radiation Oncologists

Dr. Misael C. Cruz

Designation

Speciality

Qualification

License number

Dr. Gonzalo C. Banuelos, Jr.
MD, FPCR, FPROS, FPSO

Dr. Jerickson Abbie S. Flores
MD, FPSO, FPCR, DPBR-RO

Dr. Karl Jeremy B. Lo
MD, MBA, RN, DPBR

Dra. Cynthia Tan-Pusag
MD, FPROS

Dra. Fritzie C. Villegas
M.D., DPCR, FPROS